Clinicians will soon be able to offer postmenopausal women transdermal estrogen therapy that delivers half the dose of the lowest currently available dose of transdermal estrogen. The FDA recently approved estradiol transdermal system (Menostar, Berlex) 14 mcg/d for the prevention of postmenopausal osteoporosis. The product will be available later this summer.
